Clinical trials: Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplant
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction.
- Trial name
- NCT05722210
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p
Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma
RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving chemotherapy drugs, such as fludarabine phosphate and melphalan, and total marrow irradiation before a donor…
- Conditions
- Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma
- Trial name
- NCT01163357
- Testing
- bortezomib, fludarabine phosphate, melphalan
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the…
- Conditions
- Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant
- Trial name
- ALLELE (NCT03394365)
- Testing
- tabelecleucel
- Where
- 71 sites in United States, Australia and 7 more
- Volunteers
- 115 people
- Sponsor
- Pierre Fabre Medicament
IDH1 Mutation, Acute Myeloid Leukemia (AML)
Ivosidenib as Post-HSCT Maintenance for AML
This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).
- Conditions
- IDH1 Mutation, Acute Myeloid Leukemia (AML), Hematopoietic Stem Cell Transplant (HSCT)
- Trial name
- NCT06707493
- Testing
- Ivosidenib
- Where
- 7 sites in United States
- Volunteers
- 75 people
- Sponsor
- Massachusetts General Hospital
Hematopoietic Stem Cell Transplant
Early Cognitive Behavioral Therapy for Insomnia (CBT-I) in People Planning to Under Hematopoietic Stem Cell Transplant (HSCT)
This proposed study is a prospective, randomized, controlled Phase 1 clinical trial to determine feasibility, acceptability (Aim 1) and preliminary effect (Aim 2) to mitigate insomnia symptoms and fatigue and improve…
- Trial name
- NCT07774039
- Testing
- Cognitive behavioral therapy for insomnia (CBT-I)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Hematopoietic Stem Cell Transplant
Positive Psychology Intervention for Hematopoietic Stem Cell Transplantation Survivors
This randomized clinical trial is evaluating the impact of a positive psychology intervention (PATH) on anxiety symptoms, depression symptoms, and quality of life in survivors of hematopoietic stem cell transplant (HSCT) compared…
- Trial name
- PATH-4 (NCT06328127)
- Testing
- PATH
- Where
- 3 sites in United States
- Volunteers
- 400 people
- Sponsor
- Brigham and Women's Hospital
Myelofibrosis, Acute Leukemia
Peri-graft Cytokine Profile: Influence of Hematologic Disease and Donor Type
Cytokine profiles in the early post-transplant phase may influence the Development of early post-transplant inflammatory or immunological complications.
- Conditions
- Myelofibrosis, Acute Leukemia, Myelodysplastic Syndrome, Hematopoietic Stem Cell Transplant (HSCT)
- Trial name
- Cytokinegreffe (NCT07805746)
- Testing
- Blood sampling
- Volunteers
- 96 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematopoietic Stem Cell Transplant
Oral Supplementation of 2'-Fucosyllactose in Allogeneic Bone Marrow Transplant Recipients
High dose chemotherapy and radiation used as preparative regimens in patients undergoing an allogeneic hematopoietic stem cell transplant (HSCT) disrupts intestinal homeostasis by damaging the intestinal epithelium and altering…
- Trial name
- NCT04263597
- Testing
- 2'-fucosyllactose
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Enteral Nutrition Versus Standard of Care in Allogeneic Hematopoietic Stem Cell Transplantation
This is a randomized controlled phase II trial which will enroll 112 patients with a diagnosis of a blood cancer or a serious blood disorder who plan to undergo an allogenic hematopoietic stem cell transplant using any…
- Trial name
- NCT07315165
- Testing
- Enteral Nutrition
- Where
- United States
- Volunteers
- 112 people
- Sponsor
- University of Nebraska
Busulfan Pharmacokinetic Analysis, Busulfan Dosing
26DT052; Scaling Busulfan Dose to Body Surface Area in Children
The goal of this pilot study is to determine if scaling the first busulfan dose to Body Surface Area (BSA) in children with a BSA ≥0.5 m2 and using a BSA-banded dosing table for infants (BSA <0.5 m2) increases the fraction of…
- Conditions
- Busulfan Pharmacokinetic Analysis, Busulfan Dosing, Hematopoietic Stem Cell Transplant (HSCT), Busulfan
- Trial name
- NCT07792369
- Testing
- Busulfan (BU)
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Children's Hospital of Philadelphia
Hematopoietic Stem Cell Transplant
Meaning-Centered Psychotherapy for Addressing Existential Distress of Patient/Caregiver Dyads Following Hematopoietic Stem Cell Transplantation: Feasibility and Acceptability
The purpose of this study is to learn whether Meaning-Centered Psychotherapy (MCP-Dyad) is practical, acceptable, and helpful to survivors and caregivers during recovery after stem cell transplant.
- Trial name
- NCT07595146
- Testing
- Meaning-Centered Psychotherapy, Usual Care
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Acute Myeloid Leukemia, Consolidation Therapy
Venetoclax Combined With Azacitidine for Consolidation Therapy in AML
The goal of this clinical trial is to compare the efficacy and safety of a venetoclax-based consolidation therapy versus conventional consolidation chemotherapy in newly diagnosed adult patients with high-risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Consolidation Therapy, Venentoclax, High Risk
- Trial name
- NCT07425782
- Testing
- Ara-C Group, VEN/AZA condsolidation
- Where
- China
- Volunteers
- 216 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Hematologic Malignancies, Hematopoietic Stem Cell Transplant (HSCT)
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
The purpose of this research study is to try to see whether an experimental drug, PUL 042 Inhalation Solution (PUL 042), is effective in reducing the severity of lung infections in patients with hematologic malignancies and…
- Trial name
- NCT06665100
- Testing
- PUL-042
- Where
- 12 sites in United States
- Volunteers
- 100 people
- Sponsor
- Pulmotect, Inc.
Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
The purpose of this study is to assess the efficacy and safety of tabelecleucel in participants with EBV-associated diseases.
- Conditions
- Epstein-Barr Virus (EBV)-Associated Diseases, EBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD), EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD), EBV+ Posttransplant Lymphoproliferative Disease in Central Nervous System (EBV+ CNS PTLD)
- Trial name
- NCT04554914
- Testing
- Tabelecleucel
- Where
- 40 sites in United States, Austria and 5 more
- Volunteers
- 190 people
- Sponsor
- Pierre Fabre Medicament
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor
Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant
This trial uses blood samples to understand how patients' bodies process and respond to a drug called cyclophosphamide given after a donor stem cell transplant.
- Conditions
- Allogeneic Hematopoietic Stem Cell Transplant Recipient, Donor, Malignant Neoplasm
- Trial name
- NCT04160390
- Testing
- Biospecimen Collection-Blood, Biospecimen Collection-Stool
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Thrombotic Microangiopathy, Hematopoietic Stem Cell Transplant
A Study Using Real-world Data to Examine Outcomes in Children and Adults Who Develop a Blood Clotting Disorder Called Thrombotic Microangiopathy (TMA) After Undergoing a Hematopoietic Stem Cell Transplant (HSCT).
The purpose of this study was to assess OS outcomes in pediatric (≥ 28 days of age at the time of HSCT-TMA diagnosis) and adult participants diagnosed with HSCT-TMA(referred to as TMA from hereon) within 52 weeks after HSCT and…
- Trial name
- ALX-TMA-502 (NCT07732361)
- Where
- 43 sites in United States, Belgium and 8 more
- Volunteers
- 307 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease
Study to Evaluate the Safety and Effectiveness of Withaferin A as a Treatment to Prevent GvHD in Transplant Patients
What is acute Graft versus host disease (aGvHD)? GvHD is a complication that can occur after an allogeneic stem cell transplant resulting in damage to some organs. The death rate of GvHD patients is 15-40%.
- Conditions
- Hematopoietic Stem Cell Transplant (HSCT), GVHD - Graft-Versus-Host Disease, Hematological Malignancy
- Trial name
- NCT07724873
- Testing
- SWA (standardized root extract of Withania somnifera)
- Where
- 2 sites in India
- Volunteers
- 54 people
- Sponsor
- Tata Memorial Centre
Haploidentical Hematopoietic Stem Cell Transplant, Hematological Malignancies
To Study Lower Dose of Cyclophosphamide After Stem Cell Transplant for Blood Cancers
Cyclophosphamide is the name of a medicine given to prevent graft-versus-host-disease (GVHD) after half-matched transplant. This medicine is given on the 3rd and 4th day after stem cell transplant.
- Trial name
- NCT07719946
- Testing
- Cyclophosphamide
- Where
- 2 sites in India
- Volunteers
- 20 people
- Sponsor
- Tata Memorial Centre
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant
This phase IV trial studies how well Gardasil 9 vaccine works in preventing human papillomavirus (HPV) infection in patients with hematologic malignancies who are undergoing donor stem cell transplant.
- Trial name
- NCT03023631
- Testing
- Recombinant Human Papillomavirus Nonavalent Vaccine
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Hematopoietic Stem Cell Transplant, CAR-T Cell Therapy
Coping Skills Training for Symptom Management and Daily Steps (Step Up)
The aim of this study is to test the efficacy of a hybrid in-person and mHealth coping skills training and activity coaching intervention (Step Up), to enable HCT patients to effectively cope with symptoms (pain, fatigue, and…
- Trial name
- NCT06575712
- Testing
- Step Up, Usual Care Plus (UC+)
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Duke University